Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of the Switch From Oral Selexipag to Intravenous Selexipag in Subjects With Stable Pulmonary Arterial Hypertension

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent form prior to any study-mandated procedure.~* Male and female subjects aged from 18 to 75 years (inclusive),~* Subjects with stable pulmonary arterial hypertension (PAH) defined as WHO Functional Class I-III at Visit 1 and Visit 2, and no change (i.e., introduction or dose change) in PAH-specific medication (i.e., ERA, PDE-5 inhibitor or sGC stimulator) and diuretics in the last 28 days prior to Visit 2.~* Subjects currently treated with Uptravi® at a stable dose (i.e. unchanged dose) for at least 28 days before Visit 2.~* Women of childbearing potential must have a negative pregnancy test at Visit 1 (screening) and Visit 2.~Exclusion Criteria:~* Pregnant, planning to become pregnant or lactating.~* Known and documented moderate or severe hepatic impairment.~* Subjects having received gemfibrozil at any time since initiation of Uptravi®.~* Treatment with any prostacyclin and prostacyclin analogs within 28 days prior to Visit 1.~* SBP \< 90 mmHg at Visit 1 or at Visit 2.~* Known or suspected uncontrolled hyperthyroidism.~* Severe renal failure and ongoing or planned dialysis.~* Any known factor or disease that might interfere with treatment compliance, study conduct, or interpretation of the results.~* Known concomitant life-threatening disease with a life expectancy \< 12 months.~* Treatment with another investigational treatment within 3 months of Visit 1.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Selexipag (Type: EXPERIMENTAL): Subjects with stable pulmonary arterial hypertension (PAH) and currently treated with a stable oral dose of Uptravi will be switched to i.v. selexipag from Day 2 to Day 3 (2 infusions on Day 2 and 1 infusion on Day 3). Otherwise, they will continue with their current oral selexipag treatment throughout the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).